Multiple Myeloma Trial Landscape (November 2026)

Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

550
Recruiting
232
Phase 1
222
Phase 2
71
Phase 3
17
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for multiple myeloma trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

CAR-T cellular therapy
106
Bispecific antibody
71
Cereblon / IMiD modulator
61
Monoclonal antibody
29
Other / unclassified
20
Other inhibitor
15
Antibody-drug conjugate (ADC)
15
Proteasome inhibitor
13
Small-molecule inhibitor
5
Chemotherapy
3
Kinase inhibitor (other)
3
CAR-NK cellular therapy
3

Recently Updated Trials

NCTPhaseTitleMechanism
NCT062927801, 2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)BCMA -- bispecific antibody (Linvoseltamab)
NCT056519321A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaMMSET (NSD2/WHSC1) -- small molecule inhibitor
NCT072227613A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)BCMA -- bispecific antibody (T cell engager); Proteasome -- proteasome inhibitor; CD38 -- monoclonal antibody; glucocorticoid receptor -- steroid; Cereblon modulator -- immunomodulation
NCT075559383Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaFcRH5 -- bispecific antibody
NCT067684891A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple MyelomaUnknown mechanism

Top Sponsors

SponsorRecruiting trials
Institute of Hematology & Blood Diseases Hospital, China30
Janssen Research & Development, LLC12
Regeneron Pharmaceuticals10
Memorial Sloan Kettering Cancer Center10
Xuzhou Medical University9

Geographic Distribution

Countries/regions with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country/region.

United States
227
China
175
France
59
Spain
56
Australia
44
United Kingdom
42
Canada
41
Germany
39
Japan
34
Italy
32

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Jun 30, 2027NCT06435910Engineered Dendritic Cell Vaccines for Multiple MyelomaTumor antigens -- dendritic cell vaccine
Jun 30, 2027NCT06006741Universal CAR-T Cells Targeting Multiple MyelomaMultiple myeloma antigens -- universal chimeric antigen receptor T cell therapy (CAR-T)
Apr 12, 2027NCT07463807Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentBCMA + CD3 -- bispecific antibody (teclistamab); Cereblon modulator (pomalidomide); Proteasome inhibitor (carfilzomib)
Dec 31, 2026NCT06429150Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or PlasmacytomaMultiple myeloma antigens -- CAR-T cell therapy
Dec 31, 2026NCT03271632Multi-CAR T Cell Therapy in the Treatment of Multiple MyelomaMultiple cancer cell surface antigens -- chimeric antigen receptor (CAR) T cell therapy
Dec 1, 2026NCT07600151Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaCD38 -- monoclonal antibody (isatuximab); Proteasome -- proteasome inhibitor (bortezomib); Cereblon -- immunomodulatory agent (lenalidomide); Glucocorticoid receptor -- corticosteroid (dexamethasone); Unknown mechanism (etentamig)
Dec 1, 2026NCT07612787A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple MyelomaBCMA -- CAR-T cells and bispecific antibody
Dec 2026NCT07831122Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)BCMA + CD3 -- bispecific antibody (cevostamab); BCMA -- antibody-drug conjugate (belantamab mafodotin)

You've seen the multiple myeloma landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.